메뉴 건너뛰기




Volumn 16, Issue 4, 2004, Pages 393-398

Infectious complications of treatment with biologic agents

Author keywords

Infection; Tuberculosis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B DEOXYCHOLATE; COTRIMOXAZOLE; ETANERCEPT; FLUCONAZOLE; INFLIXIMAB; ISONIAZID; ITRACONAZOLE; PYRAZINAMIDE; RIFAMPICIN; VORICONAZOLE;

EID: 3042527166     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000127594.92432.7c     Document Type: Review
Times cited : (86)

References (45)
  • 1
    • 0038719635 scopus 로고    scopus 로고
    • Infections and biological therapy in rheumatoid arthritis
    • Cunnane G, Doran M, Bresnihan B: Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003, 17:345-363. A thorough review of background infections in persons with RA, and those treated with traditional and new, biological therapies.
    • (2003) Best Pract Res Clin Rheumatol , vol.17 , pp. 345-363
    • Cunnane, G.1    Doran, M.2    Bresnihan, B.3
  • 2
    • 0036231929 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases
    • Criscione LG, St Clair EW: Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002, 14:204-211. A good review of mechanism of action and relative effectiveness of the currently available TNF-α inhibitors.
    • (2002) Curr Opin Rheumatol , vol.14 , pp. 204-211
    • Criscione, L.G.1    St Clair, E.W.2
  • 3
    • 0037819344 scopus 로고    scopus 로고
    • An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
    • Published erratum appears in Ann Oncol 2003, 14:967
    • Boye J, Elter T, Engert A: An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003,14:520-535. [Published erratum appears in Ann Oncol 2003, 14:967.]
    • (2003) Ann Oncol , vol.14 , pp. 520-535
    • Boye, J.1    Elter, T.2    Engert, A.3
  • 4
    • 0035091343 scopus 로고    scopus 로고
    • Antibody-targeted immunotherapy for treatment of malignancy
    • Published erratum appears in Annu Rev Med 2002, 53:xi
    • White CA, Weaver RL, Grillo-Lopez AJ: Antibody-targeted immunotherapy for treatment of malignancy. Ann Med 2001, 52:125-145. [Published erratum appears in Annu Rev Med 2002, 53:xi.]
    • (2001) Ann Med , vol.52 , pp. 125-145
    • White, C.A.1    Weaver, R.L.2    Grillo-Lopez, A.J.3
  • 5
    • 0042887615 scopus 로고    scopus 로고
    • An overview of targeted treatments in cancer
    • Abou-Jawde R, Choueiri T, Alemany C, et al.: An overview of targeted treatments in cancer. Clin Ther 2003, 25:2121-2137.
    • (2003) Clin Ther , vol.25 , pp. 2121-2137
    • Abou-Jawde, R.1    Choueiri, T.2    Alemany, C.3
  • 7
    • 0037373957 scopus 로고    scopus 로고
    • Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management
    • Gardam MA, Keystone EC, Menzies R, et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155. [See comment.] A concise and accurate review of the pathophysiology of TB infection and disease and how TNF-α inhibitors disrupt the balance. The suggested approach to clinical care is one of several suggested plans.
    • (2003) Lancet Infect Dis , vol.3 , pp. 148-155
    • Gardam, M.A.1    Keystone, E.C.2    Menzies, R.3
  • 8
    • 0036569910 scopus 로고    scopus 로고
    • TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection
    • Roach DR, Bean AGD, Demangel C, et al.: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168:4620-4627.
    • (2002) J Immunol , vol.168 , pp. 4620-4627
    • Roach, D.R.1    Bean, A.G.D.2    Demangel, C.3
  • 9
    • 0028979703 scopus 로고
    • Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
    • Flynn JL, Goldstein MM, Chan J, et al.: Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
    • (1995) Immunity , vol.2 , pp. 561-572
    • Flynn, J.L.1    Goldstein, M.M.2    Chan, J.3
  • 10
    • 0345421272 scopus 로고    scopus 로고
    • Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis
    • Lopez-Maderuelo D, Arnalich F, Serantes R, et al.: Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 167:970-975. [See comment.]
    • (2003) Am J Respir Crit Care Med , vol.167 , pp. 970-975
    • Lopez-Maderuelo, D.1    Arnalich, F.2    Serantes, R.3
  • 11
    • 0037385118 scopus 로고    scopus 로고
    • Interferon-gamma and host susceptibility to tuberculosis
    • Bellamy R: Interferon-gamma and host susceptibility to tuberculosis. Am J Respir Crit Care Med 2003, 167:946-947. [See comment.] Excellent background reading for other cytokines involved in immunity to TB.
    • (2003) Am J Respir Crit Care Med , vol.167 , pp. 946-947
    • Bellamy, R.1
  • 12
    • 0344393427 scopus 로고    scopus 로고
    • Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells
    • Lewinsohn DA, Heinzel AS, Gardner JM, et al.: Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 2003, 168:1346-1352.
    • (2003) Am J Respir Crit Care Med , vol.168 , pp. 1346-1352
    • Lewinsohn, D.A.1    Heinzel, A.S.2    Gardner, J.M.3
  • 13
    • 0038290255 scopus 로고    scopus 로고
    • High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis
    • Koguchi Y, Kawakami K, Uezu K, et al.: High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 2003, 167:1355-1359.
    • (2003) Am J Respir Crit Care Med , vol.167 , pp. 1355-1359
    • Koguchi, Y.1    Kawakami, K.2    Uezu, K.3
  • 14
    • 0036255252 scopus 로고    scopus 로고
    • Immune function in patients with rheumatoid arthritis treated with etanercept
    • Moreland LW, Bucy RP, Weinblatt ME, et al.: Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002, 103:13-21.
    • (2002) Clin Immunol , vol.103 , pp. 13-21
    • Moreland, L.W.1    Bucy, R.P.2    Weinblatt, M.E.3
  • 15
    • 0038216657 scopus 로고    scopus 로고
    • Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy
    • Wood KL, Hage CA, Knox KS, et al.: Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003, 167:1279-1282.
    • (2003) Am J Respir Crit Care Med , vol.167 , pp. 1279-1282
    • Wood, K.L.1    Hage, C.A.2    Knox, K.S.3
  • 16
    • 0036167283 scopus 로고    scopus 로고
    • Experience with etanercept in an academic medical center: Are infection rates increased?
    • Phillips K, Husni ME, Karlson EW, et al.: Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002, 47:17-21.
    • (2002) Arthritis Rheum , vol.47 , pp. 17-21
    • Phillips, K.1    Husni, M.E.2    Karlson, E.W.3
  • 17
    • 0035846326 scopus 로고    scopus 로고
    • Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
    • Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104. The original description of cases of TB reported to the FDA associated with infliximab. It is limited in that it is a retrospective review of voluntarily reported cases, but gives an important view of the type of disease seen.
    • (2001) N Engl J Med , vol.345 , pp. 1098-1104
    • Keane, J.1    Gershon, S.2    Wise, R.P.3
  • 18
    • 0041653315 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report
    • Gomez-Reino JJ, Carmona L, Valverde VR, et al.: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127. Large active-surveillance report of patients treated with a combination of TNF-α inhibitors, though infliximab predominantly.
    • (2003) Arthritis Rheum , vol.48 , pp. 2122-2127
    • Gomez-Reino, J.J.1    Carmona, L.2    Valverde, V.R.3
  • 19
    • 3042555988 scopus 로고    scopus 로고
    • Reported TB in the United States, Surveillance Reports: 2000
    • Centers for Disease Control: Reported TB in the United States, Surveillance Reports: 2000. MMWR Morb Mortal Wkly Rep 2001.
    • (2001) MMWR Morb Mortal Wkly Rep
  • 20
    • 0036157584 scopus 로고    scopus 로고
    • Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor
    • Wagner TE, Huseby ES, Huseby JS: Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor. Am J Med 2002, 112:67-69. [See comment.]
    • (2002) Am J Med , vol.112 , pp. 67-69
    • Wagner, T.E.1    Huseby, E.S.2    Huseby, J.S.3
  • 21
    • 0032582422 scopus 로고    scopus 로고
    • Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
    • Centers for Disease Control and Prevention
    • Anonymous: Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998, 47:1-58.
    • (1998) MMWR Morb Mortal Wkly Rep , vol.47 , pp. 1-58
  • 22
    • 0036839233 scopus 로고    scopus 로고
    • Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents
    • Furst DE, Cush J, Kaufmann S, et al.: Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002, 61:(suppl 3). A U.S. view of what to do to diagnose and treat TB in the setting of TNF-α inhibitor therapy.
    • (2002) Ann Rheum Dis , vol.61 , Issue.3 SUPPL.
    • Furst, D.E.1    Cush, J.2    Kaufmann, S.3
  • 23
    • 0242416978 scopus 로고    scopus 로고
    • French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers
    • Mariette X, Salmon D: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003, 62:791. A French view of what to do to diagnose and treat TB in the setting of TNF-α inhibitor therapy.
    • (2003) Ann Rheum Dis , vol.62 , pp. 791
    • Mariette, X.1    Salmon, D.2
  • 24
    • 0042073062 scopus 로고    scopus 로고
    • Tuberculosis in the cytokine era: What rheumatologists need to know
    • Hamilton CD: Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 2003, 48:2085-2091. This authors view of how clinicians should approach diagnosis, prevention and treatment of TB infection and disease.
    • (2003) Arthritis Rheum , vol.48 , pp. 2085-2091
    • Hamilton, C.D.1
  • 25
    • 0037337133 scopus 로고    scopus 로고
    • Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection
    • Castro KG, Jereb JA, Koppaka VR, et al.: Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest 2003, 123:967.
    • (2003) Chest , vol.123 , pp. 967
    • Castro, K.G.1    Jereb, J.A.2    Koppaka, V.R.3
  • 26
    • 0037445288 scopus 로고    scopus 로고
    • Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis
    • Stout JE, Engemann JJ, Cheng AC, et al.: Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003, 167:824-827.
    • (2003) Am J Respir Crit Care Med , vol.167 , pp. 824-827
    • Stout, J.E.1    Engemann, J.J.2    Cheng, A.C.3
  • 27
    • 0037245531 scopus 로고    scopus 로고
    • Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis-improved completion rates but more hepatotoxicity
    • McNeill L, Allen M, Estrada C, et al.: Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis-improved completion rates but more hepatotoxicity. Chest 2003, 123:102-106.
    • (2003) Chest , vol.123 , pp. 102-106
    • McNeill, L.1    Allen, M.2    Estrada, C.3
  • 28
    • 0035980174 scopus 로고    scopus 로고
    • Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001
    • Anonymous: Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001, 50:733-735.
    • (2001) MMWR Morb Mortal Wkly Rep , vol.50 , pp. 733-735
  • 29
    • 0034625247 scopus 로고    scopus 로고
    • Targeted tuberculin testing and treatment of latent tuberculosis infection
    • American Thoracic Society
    • Anonymous: Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Morb Mortal Wkly Rep 2000, 49:1-51.
    • (2000) MMWR Morb Mortal Wkly Rep , vol.49 , pp. 1-51
  • 30
    • 0018102991 scopus 로고
    • Histoplasmosis in immunosuppressed patients
    • Kauffman CA, Israel KS, Smith JW, et al.: Histoplasmosis in immunosuppressed patients. Am J Med 1978, 64:923-932.
    • (1978) Am J Med , vol.64 , pp. 923-932
    • Kauffman, C.A.1    Israel, K.S.2    Smith, J.W.3
  • 31
    • 0021985799 scopus 로고
    • Histoplasmosis in the acquired immune deficiency syndrome
    • Wheat LJ, Slama TG, Zeckel ML: Histoplasmosis in the acquired immune deficiency syndrome. Am J Med 1985, 78:203-210.
    • (1985) Am J Med , vol.78 , pp. 203-210
    • Wheat, L.J.1    Slama, T.G.2    Zeckel, M.L.3
  • 32
    • 84948009081 scopus 로고
    • Histoplasmosis in renal allograft recipients. Two large urban outbreaks
    • Wheat LJ, Smith EJ, Sathapatayavongs B, et al.: Histoplasmosis in renal allograft recipients. Two large urban outbreaks. Arch Intern Med 1983, 143:703-707.
    • (1983) Arch Intern Med , vol.143 , pp. 703-707
    • Wheat, L.J.1    Smith, E.J.2    Sathapatayavongs, B.3
  • 33
    • 0031941570 scopus 로고    scopus 로고
    • Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma
    • Zhou P, Miller G, Seder RA: Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol 1998, 160:1359-1368.
    • (1998) J Immunol , vol.160 , pp. 1359-1368
    • Zhou, P.1    Miller, G.2    Seder, R.A.3
  • 34
    • 0036822552 scopus 로고    scopus 로고
    • Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept
    • Lee JH, Slifman NR, Gershon SK, et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
    • (2002) Arthritis Rheum , vol.46 , pp. 2565-2570
    • Lee, J.H.1    Slifman, N.R.2    Gershon, S.K.3
  • 35
    • 0033084013 scopus 로고    scopus 로고
    • Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis
    • Mehrad B, Strieter RM, Standiford TJ: Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999, 162:1633-1640.
    • (1999) J Immunol , vol.162 , pp. 1633-1640
    • Mehrad, B.1    Strieter, R.M.2    Standiford, T.J.3
  • 36
    • 0031741636 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus
    • Roilides E, Dimitriadou-Georgiadou A, Sein T, et al.: Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998, 66:5999-6003.
    • (1998) Infect Immun , vol.66 , pp. 5999-6003
    • Roilides, E.1    Dimitriadou-Georgiadou, A.2    Sein, T.3
  • 37
    • 0141956267 scopus 로고    scopus 로고
    • Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis
    • Steinbach WJ, Stevens DA: Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003, 37(suppl 87). Thorough review of newer antifungal agents specifically for invasive aspergillosis, but many of which will be effective against other fungal pathogens.
    • (2003) Clin Infect Dis , vol.37 , Issue.87 SUPPL.
    • Steinbach, W.J.1    Stevens, D.A.2
  • 38
    • 0346993413 scopus 로고    scopus 로고
    • Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy
    • Hage CA, Wood KL, Winer-Muram HT, et al.: Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003, 124:2395-2397.
    • (2003) Chest , vol.124 , pp. 2395-2397
    • Hage, C.A.1    Wood, K.L.2    Winer-Muram, H.T.3
  • 39
    • 0028291633 scopus 로고
    • Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs
    • van Furth R, van Zwet TL, Buisman AM, et al.: Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 1994, 170:234-237.
    • (1994) J Infect Dis , vol.170 , pp. 234-237
    • Van Furth, R.1    Van Zwet, T.L.2    Buisman, A.M.3
  • 40
    • 0027327619 scopus 로고
    • Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
    • Rothe J, Lesslauer W, Lotscher H, et al.: Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364:798-802.
    • (1993) Nature , vol.364 , pp. 798-802
    • Rothe, J.1    Lesslauer, W.2    Lotscher, H.3
  • 41
    • 0027297663 scopus 로고
    • Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxio shock, yet succumb to L. monocytogenes infection
    • Pfeffer K, Matsuyama T, Kundig TM, et al.: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxio shock, yet succumb to L. monocytogenes infection. Cell 1993, 73:457-467.
    • (1993) Cell , vol.73 , pp. 457-467
    • Pfeffer, K.1    Matsuyama, T.2    Kundig, T.M.3
  • 42
    • 0037331223 scopus 로고    scopus 로고
    • Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents
    • Slifman NR, Gershon SK, Lee JH, et al.: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003, 48:319-324.
    • (2003) Arthritis Rheum , vol.48 , pp. 319-324
    • Slifman, N.R.1    Gershon, S.K.2    Lee, J.H.3
  • 43
    • 0036675377 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: Report of two cases
    • Gluck T, Linde HJ, Scholmerich J, et al.: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002, 46:2255-2257.
    • (2002) Arthritis Rheum , vol.46 , pp. 2255-2257
    • Gluck, T.1    Linde, H.J.2    Scholmerich, J.3
  • 44
    • 85081146363 scopus 로고    scopus 로고
    • Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: Comment on the letter by Gluck et al
    • Aparicio AG, Munoz-Fernandez S, Bonilla G, et al.: Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum 2003, 48:1764-1765.
    • (2003) Arthritis Rheum , vol.48 , pp. 1764-1765
    • Aparicio, A.G.1    Munoz-Fernandez, S.2    Bonilla, G.3
  • 45
    • 0036673687 scopus 로고    scopus 로고
    • Pneumocystis carinii pneumonia following a second infusion of infliximab
    • Tai TL, O'Rourke KP, McWeeney M, et al.: Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002, 41:951-952.
    • (2002) Rheumatology , vol.41 , pp. 951-952
    • Tai, T.L.1    O'Rourke, K.P.2    McWeeney, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.